Novel products for haemostasis - current status

Haemophilia

Volumn 20, Issue S4, 2014, Pages 23-28

  Oldenburg, J ^a   Albert, T ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Haemophilia; Half life; Long acting clotting factor; Novel products; Pharmacokinetic

Indexed keywords

ACE 910; ALBUMIN; ANTITHROMBIN; BAX 855; BAY 94 9027; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR CONCENTRATE; CYSTEINE; DRUG ANTIBODY; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G; MACROGOL; MONOCLONAL ANTIBODY 2012; N 8GP; N 9GP; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; SMALL INTERFERING RNA; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANTIGENICITY; BIOENGINEERING; COVALENT BOND; DRUG HALF LIFE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOGENICITY; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; QUALITY OF LIFE; REVIEW; SITE DIRECTED MUTAGENESIS; ANIMAL; BIOTECHNOLOGY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; PHYSIOLOGY; RNA INTERFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTITHROMBIN PROTEINS; ANTITHROMBINS; BIOTECHNOLOGY; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMOSTASIS; HUMANS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RNA INTERFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84899567922     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12428     Document Type: Review

References (45)

1. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood 2013; 122: 3568-74.
2. Knobe K, Berntorp E. New treatments in hemophilia: insights for the clinician. Ther Adv Hematol 2012; 3: 165-75.
3. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11(Suppl. 1): 84-98.
4. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008; 5: 371-83.
5. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012; 161: 461-72.
6. Stennicke HR, Kjalke M, Karpf DM et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108-16.
7. Tiede A, Brand B, Fischer R et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
8. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
9. Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant FVIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014. prepublished ahead of print doi:10.1111/jth.12506.
10. Turecek PL, Bossard MJ, Graninger M et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32(Suppl. 1): S29-38.
11. Østergaard H, Bjelke JR, Hansen L et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
12. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial I patients with hemophilia B. Blood 2011; 118: 2695-701.
13. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 2004; 101: 11076-81.
14. Dumont JA, Liu T, Low SC et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119: 3024-30.
15. Peters RT, Toby G, Lu Q et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013; 11: 132-41.
16. Mahlangu J, Powell JS, Ragni MV et al. A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
17. Oldenburg J, Shapiro AD, Ragni MV et al. Dosing intervals and bleeding rates before and following treatment with recombinant factor VIII FC fusion protein in patients with severe Haemophilia A: Experience from the ALong Clinical Study. Haemophilia 2014; 20 S2 abstract 1129.
18. Peters RT, Low SC, Kamphaus GD et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-64.
19. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
20. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23.
21. Schulte S. Challenges for new haemophilia products from a manufacturer's perspective. Thromb Res 2013. doi:10.1016/j.thromres.2013.10.021. [Epub ahead of print].
22. Schulte S. Innovative coagulation factors: albumin fusion technology an recombinant single-chain factor VIII. Thromb Res 2013; 131(Suppl. 2): S2-6.
23. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
24. Schmidbauer S, Witzel R, Kreuter J et al. Physico-chemical characterization of recombinant single chain FVIII. Hämostaseologie 2012; 32(Suppl. 1): A41; P2-29.
25. Zollner SB, Raquet E, Müller-Cohrs J et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res 2013; 132: 280-7.
26. Kitazawa T, Igawa T, Sampei Z et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570-4.
27. Sampei Z, Igawa T, Soeda T et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8: e57479.
28. Ogiwara K, Nogami K, Yada K et al. A novel bispecific antibody (ACE910) against coagulation factors IXa and X improves procoagulant activity of patients with hemophilia A ex vivo to hemostatic level. J Thromb Haemost 2013; 11(Suppl. S2): 169.
29. Hilden I, Lauritzen B, Sørensen BB et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119: 5871-8.
30. Chowdary P, Friedrich U, Lethagen S, Angchaisuksiri P. A new treatment concept for haemophilia: safety, pharmacokinetics and pharmacodynamics of single i.v. and s.c. doses of a monoclonal anti-TFPI antibody in healthy males and haemophilia subjects. J Thromb Haemost 2013; 11(Suppl. S2): 460.
31. Salas J, Tan S, Kistanova E et al. A fusion of thrombin-activatable FVII and soluble tissue factor displays improved activity and pharmacokinetic properties compared to activated FVII. J Thromb Haemost 2013; 11(Suppl. S2): 208.
32. Hart G, Hershkovitz O, Bar-Ilan A, Fima E. A long-acting FVIIa-CTP proposing an improved prophylactic and on demand treatment for hemophilic patients following SC and IV administration-evaluation in animal models. J Thromb Haemost 2013; 11(Suppl. S2): 268-9.
33. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119: 5111-7.
34. ®)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; 17: 854-9.
35. Sandberg H, Kannicht C, Stenlund P et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012; 130: 808-17.
36. Ehrlich HJ, Wong WY, Ewenstein BM et al. Development of novel treatmentoptions for patients with haemophilia. Hämostaseologie 2013; 33(Suppl. 1): S36-8.
37. Powell J, Martinowitz U, Windyga J et al. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost 2012; 108: 913-22.
38. Pan J, Liu T, Kim JY et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood 2009; 114: 2802-11.
39. Dockal M, Pachlinger R, Hartmann R et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antago- nistic aptamer BAX 499. Blood (ASH Annual Meeting Abstracts) 2012; 120: 1104.
40. Møss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011; 9: 1368-74.
41. Mahlangu J, Karim FA, Gorska-Kosicka M et al. Anti-drug antibody formation in haemophilia patients with inhibitors after receiving recombinant activated FVII analogue (vatreptacog alfa). Haemophilia 2013; 19(Suppl. 2), 10-82, PO029.
42. Mahlangu JN, Coetzee MJ, Laffan M et al. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 2012; 10: 773-80.
43. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
44. Sommer JM, Moore N, McGuffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294-300.
45. Gu JM, Ramsey P, Evans V et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014. doi:10.1111/hae.12374. [Epub ahead of print].